• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Analysis of the efficacy and survival of ixazomib-containing regimens in patients with refractory and relapsed multiple myeloma].

作者信息

Yang C, Zhuang J L

机构信息

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):680-684. doi: 10.3760/cma.j.issn.0253-2727.2022.08.011.

DOI:10.3760/cma.j.issn.0253-2727.2022.08.011
PMID:36709154
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9593011/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d783/9593011/1caaa83b6d35/cjh-43-08-680-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d783/9593011/f4a392ef4bdb/cjh-43-08-680-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d783/9593011/1caaa83b6d35/cjh-43-08-680-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d783/9593011/f4a392ef4bdb/cjh-43-08-680-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d783/9593011/1caaa83b6d35/cjh-43-08-680-g002.jpg

相似文献

1
[Analysis of the efficacy and survival of ixazomib-containing regimens in patients with refractory and relapsed multiple myeloma].含伊沙佐米方案治疗难治性和复发性多发性骨髓瘤患者的疗效及生存分析
Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):680-684. doi: 10.3760/cma.j.issn.0253-2727.2022.08.011.
2
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.在常规临床实践中，来那度胺和地塞米松（Rd）与伊沙佐米、来那度胺和地塞米松（IRD）相比，对复发和难治性多发性骨髓瘤患者的生存获益。
BMC Cancer. 2021 Jan 15;21(1):73. doi: 10.1186/s12885-020-07732-1.
3
Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.伊沙佐米、来那度胺和地塞米松联合用药用于复发/难治性多发性骨髓瘤患者的“真实世界”临床实践
Ann Hematol. 2022 Jan;101(1):81-89. doi: 10.1007/s00277-021-04663-0. Epub 2021 Sep 22.
4
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.随机、双盲、安慰剂对照的 III 期研究，评估伊沙佐米联合来那度胺-地塞米松治疗复发/难治性多发性骨髓瘤患者：中国延续研究。
J Hematol Oncol. 2017 Jul 6;10(1):137. doi: 10.1186/s13045-017-0501-4.
5
Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.在复发/难治性多发性骨髓瘤的随机、双盲、3期TOURMALINE-MM1研究中，使用伊沙佐米或安慰剂联合来那度胺-地塞米松的医疗资源利用情况。
J Med Econ. 2018 Aug;21(8):793-798. doi: 10.1080/13696998.2018.1474745. Epub 2018 May 29.
6
Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data.来那度胺/地塞米松为基础的三联方案治疗美国复发性和/或难治性多发性骨髓瘤的疗效比较：真实世界电子健康记录数据的分析。
Curr Probl Cancer. 2024 Jun;50:101078. doi: 10.1016/j.currproblcancer.2024.101078. Epub 2024 Mar 27.
7
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.伊沙佐米联合来那度胺和地塞米松治疗复发多发性骨髓瘤患者：来自真实世界数据集的17p缺失影响及对蛋白酶体抑制剂的敏感性
Leuk Lymphoma. 2021 May;62(5):1243-1246. doi: 10.1080/10428194.2020.1864356. Epub 2021 Jan 13.
8
[Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime].口服伊沙佐米-来那度胺-地塞米松方案用于复发难治性多发性骨髓瘤的长期无进展生存
Orv Hetil. 2021 Sep 5;162(36):1451-1458. doi: 10.1556/650.2021.32179.
9
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.塞利尼索、伊沙佐米和低剂量地塞米松用于复发或难治性多发性骨髓瘤患者的I期研究。
Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):198-200. doi: 10.1016/j.clml.2019.12.013. Epub 2019 Dec 26.
10
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.来那度胺或蛋白酶体抑制剂既往暴露对复发/难治性多发性骨髓瘤患者接受伊沙佐米-来那度胺-地塞米松治疗效果的影响：来自 INSURE 研究的 pooled 分析。
Eur J Haematol. 2024 Aug;113(2):190-200. doi: 10.1111/ejh.14214. Epub 2024 Apr 23.

本文引用的文献

1
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.来那度胺、达雷妥尤单抗联合低剂量地塞米松治疗新诊断的 frail 多发性骨髓瘤患者：HOVON 143 研究。
J Clin Oncol. 2021 Sep 1;39(25):2758-2767. doi: 10.1200/JCO.20.03143. Epub 2021 May 4.
2
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.来那度胺联合伊沙佐米和地塞米松治疗复发/难治性多发性骨髓瘤的真实世界疗效。
Future Oncol. 2021 Jul;17(19):2499-2512. doi: 10.2217/fon-2020-1225. Epub 2021 Mar 26.
3
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
复发和难治性多发性骨髓瘤的治疗：国际骨髓瘤工作组的建议。
Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7.
4
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.来那度胺/地塞米松/伊沙佐米治疗多发性骨髓瘤的疗效：一项多中心回顾性分析。
Eur J Haematol. 2021 Apr;106(4):555-562. doi: 10.1111/ejh.13586. Epub 2021 Jan 31.
5
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.在常规临床实践中，来那度胺和地塞米松（Rd）与伊沙佐米、来那度胺和地塞米松（IRD）相比，对复发和难治性多发性骨髓瘤患者的生存获益。
BMC Cancer. 2021 Jan 15;21(1):73. doi: 10.1186/s12885-020-07732-1.
6
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience.来那度胺、伊沙佐米和地塞米松在复发性（≥2 次复发）难治性骨髓瘤中有效且耐受性良好：一项多中心真实世界的英国经验。
Leuk Lymphoma. 2021 Jun;62(6):1396-1404. doi: 10.1080/10428194.2020.1864355. Epub 2020 Dec 25.
7
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.来那度胺-硼替佐米-地塞米松治疗复发/难治性多发性骨髓瘤的真实世界疗效和安全性。
Ann Hematol. 2020 May;99(5):1049-1061. doi: 10.1007/s00277-020-03981-z. Epub 2020 Apr 1.
8
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.基于伊沙佐米的方案治疗复发/难治性多发性骨髓瘤：真实世界数据与临床试验结果是否一致？一项多中心以色列登记研究。
Ann Hematol. 2020 Jun;99(6):1273-1281. doi: 10.1007/s00277-020-03985-9. Epub 2020 Mar 20.
9
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.口服方案伊沙佐米、泊马度胺和地塞米松用于复发/难治性多发性骨髓瘤的I/II期试验
Leukemia. 2018 Jul;32(7):1567-1574. doi: 10.1038/s41375-018-0038-8. Epub 2018 Feb 23.
10
Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016.2006-2016 年中国多发性骨髓瘤的发病率和死亡率：基于 2016 年全球疾病负担研究的分析。
J Hematol Oncol. 2019 Dec 10;12(1):136. doi: 10.1186/s13045-019-0807-5.